169 related articles for article (PubMed ID: 38435828)
1. A bioengineered anti-VEGF protein with high affinity and high concentration for intravitreal treatment of wet age-related macular degeneration.
Huang C; Wang Y; Huang J; Liu H; Chen Z; Jiang Y; Chen Y; Qian F
Bioeng Transl Med; 2024 Mar; 9(2):e10632. PubMed ID: 38435828
[TBL] [Abstract][Full Text] [Related]
2. A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.
Hutton-Smith LA; Gaffney EA; Byrne HM; Maini PK; Schwab D; Mazer NA
Mol Pharm; 2016 Sep; 13(9):2941-50. PubMed ID: 26726925
[TBL] [Abstract][Full Text] [Related]
3. Polymorphic nanobody crystals as long-acting intravitreal therapy for wet age-related macular degeneration.
Zhu S; Fan S; Tang T; Huang J; Zhou H; Huang C; Chen Y; Qian F
Bioeng Transl Med; 2023 Nov; 8(6):e10523. PubMed ID: 38023710
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal injectable hydrogel rods with long-acting bevacizumab delivery to the retina.
Lee S; Hong HK; Song JS; Jeong SI; Chung JY; Woo SJ; Park KD
Acta Biomater; 2023 Nov; 171():273-288. PubMed ID: 37739248
[TBL] [Abstract][Full Text] [Related]
5. The Safety of Anti-VEGF Treatment, in the Context of the Retinal Nerve Fibre Layer, in Patients with Wet Age-Related Macular Degeneration: A Review.
Wichrowska M; Goździewska E; Kocięcki J
Front Biosci (Landmark Ed); 2023 Sep; 28(9):222. PubMed ID: 37796711
[TBL] [Abstract][Full Text] [Related]
6. Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF Treatment.
Foss A; Rotsos T; Empeslidis T; Chong V
Ophthalmologica; 2022; 245(3):204-217. PubMed ID: 34695835
[TBL] [Abstract][Full Text] [Related]
7. [Subretinal hemorrhage after intravitreal injection of anti-VEGF for age-related macular degeneration: a retrospective study].
Baeteman C; Hoffart L; Galland F; Ridings B; Conrath J
J Fr Ophtalmol; 2009 May; 32(5):309-13. PubMed ID: 19769866
[TBL] [Abstract][Full Text] [Related]
8. [Neovascular recurrences in 42 treatment-naive eyes with neovascular age-related macular degeneration (AMD) followed for over 2 years].
Bodénès F; Massé H; Lebreton O; Weber M
J Fr Ophtalmol; 2021 May; 44(5):626-631. PubMed ID: 33840491
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of intravitreal bevacizumab and aflibercept on intraocular pressure in wet age-related macular degeneration.
Kähkönen M; Tuuminen R; Aaltonen V
BMC Ophthalmol; 2021 Aug; 21(1):312. PubMed ID: 34454473
[TBL] [Abstract][Full Text] [Related]
10. Economic Value of Anti-Vascular Endothelial Growth Factor Treatment for Patients With Wet Age-Related Macular Degeneration in the United States.
Mulligan K; Seabury SA; Dugel PU; Blim JF; Goldman DP; Humayun MS
JAMA Ophthalmol; 2020 Jan; 138(1):40-47. PubMed ID: 31725830
[TBL] [Abstract][Full Text] [Related]
11. Incidence, Risk Factors, and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-VEGF for Retinal Diseases: Data from the Fight Retinal Blindness! Registry.
Gabrielle PH; Nguyen V; Arnould L; Viola F; Zarranz-Ventura J; Barthelmes D; Creuzot-Garcher C; Gillies M;
Ophthalmol Retina; 2022 Nov; 6(11):1044-1053. PubMed ID: 35589075
[TBL] [Abstract][Full Text] [Related]
12. WRINKLED VASCULARIZED RETINAL PIGMENT EPITHELIUM DETACHMENT PROGNOSIS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Lam D; Semoun O; Blanco-Garavito R; Jung C; Nguyen DT; Souied EH; Mimoun G
Retina; 2018 Jun; 38(6):1100-1109. PubMed ID: 28520639
[TBL] [Abstract][Full Text] [Related]
13. Baseline characteristics and progression of neovascular age-related macular degeneration in patients receiving over 60 intravitreal injections of anti-vascular endothelial growth factor.
Prahs P; Brandl C; Helbig H; Volz C
Rom J Ophthalmol; 2023; 67(3):260-266. PubMed ID: 37876508
[No Abstract] [Full Text] [Related]
14. [Interest of optical coherence tomography performed immediately before intravitreal injection of anti-VEGF in exudative AMD].
Moyal L; Cohen SY; Pedinielli A; Semoun O; Lalloum F; Jung C; Souied E
J Fr Ophtalmol; 2015 Sep; 38(7):573-9. PubMed ID: 25997681
[TBL] [Abstract][Full Text] [Related]
15. [Relationship between intravitreal anti-VEGF therapy and subretinal hemorrhage in patients with exudative age-related macular degeneration].
Kauffmann Y; Isaico R; Lefebvre A; Bron AM; Creuzot-Garcher C
J Fr Ophtalmol; 2014 Mar; 37(3):195-201. PubMed ID: 24534623
[TBL] [Abstract][Full Text] [Related]
16. An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration.
Feng L; Hu JH; Chen J; Xie X
J Zhejiang Univ Sci B; 2018 Apr.; 19(4):327-332. PubMed ID: 29616508
[TBL] [Abstract][Full Text] [Related]
17. Factors That Can Prolong Ocular Treatment Duration in Age-Related Macular Degeneration.
Kaiser PK; Giani A; Fuchs H; Chong V; Heier JS
Ophthalmic Res; 2023; 66(1):653-663. PubMed ID: 36626895
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal anti-VEGF use in France: a cross-sectional and longitudinal Nationwide observational study.
Billioti de Gage S; Bertrand M; Grimaldi S; Zureik M
Acta Ophthalmol; 2022 Mar; 100(2):e502-e511. PubMed ID: 34126649
[TBL] [Abstract][Full Text] [Related]
19. Retrospective analysis of first-line anti-vascular endothelial growth factor treatment patterns in wet age-related macular degeneration.
Johnston SS; Wilson K; Huang A; Smith D; Varker H; Turpcu A
Adv Ther; 2013 Dec; 30(12):1111-27. PubMed ID: 24310208
[TBL] [Abstract][Full Text] [Related]
20. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
